Drug Industry Boosts Lobbying Coffers; Amgen Doubles Its Expenditures
Lobbyists for the pharmaceutical industry have had plenty of work this year as Congress pushed forward legislation to overhaul the patent system, mandate lower drug prices for Medicare, and clear the way for approval of generic biologics
You may also be interested in...
A House patent reform provision on apportionment of damages in infringement suits is likely to be revised, despite House passage of the legislation Sept. 7 by a vote of 220-175
Comparative effectiveness research and generic biologics are among the key pharmaceutical issues that attracted lobbying efforts by large health insurers in the first half of 2007, according to reports filed recently with Congress
As Amgen enters into a major restructuring effort that will include extensive cost-cutting and significant headcount reductions, it will also make serious adjustments to its R&D program - including scaling back from its industry-leading approach of investing a high percentage of sales on R&D